|
1. |
Clinical Pharmacokinetics of ZidovudineAn Update |
|
Clinical Pharmacokinetics,
Volume 30,
Issue 4,
1996,
Page 251-262
Edward P. Acosta,
Linda M. Page,
Courtney V. Fletcher,
Preview
|
PDF (5553KB)
|
|
摘要:
The battle against the acquired immune deficiency syndrome (AIDS) is now into its second decade, and substantial advancements have been made in our understanding of the complex life cycle of, and the immunopathology associated with, human immunodeficiency virus (HIV) infection, as well as of the drugs used to modify the course of disease.Zidovudine was the first agent approved for treatment of HIV disease, and since its widespread availability in 1987 the pharmacokinetic disposition and clinical effects of zidovudine have been extensively evaluated. This article reviews the absorption, distribution, metabolism and elimination characteristics of zidovudine, focusing on more recent information. In addition, factors that may or may not affect zidovudine disposition are discussed. These include selected drug interactions and concomitant disease states such as renal and hepatic insufficiency. Issues such as bodyweight normalisation, maternal-fetal transfer, pregnancy and intracellular phosphorylation are discussed in relation to the pharmacokinetics and clinical efficacy of zidovudine.Finally, information regarding the clinical pharmacodynamics of zidovudine is presented. This includes possible relationships between zidovudine pharmacokinetics and markers of efficacy and toxicity, and the significance of linking pharmacokinetic and pharmacodynamic information.
ISSN:0312-5963
出版商:ADIS
年代:1996
数据来源: ADIS
|
2. |
Pharmacokinetics of Quinine, Chloroquine and AmodiaquineClinical Implications |
|
Clinical Pharmacokinetics,
Volume 30,
Issue 4,
1996,
Page 263-299
Sanjeev Krishna,
Nicholas J. White,
Preview
|
PDF (15915KB)
|
|
摘要:
Malaria is associated with a reduction in the systemic clearance and apparent volume of distribution of the cinchona alkaloids; this reduction is proportional to the disease severity. There is increased plasma protein binding, predominantly to &agr;1-acid glycoprotein, and elimination half-lives (in healthy adults quinine t½z= 11 hours, quinidine t½z= 8 hours) are prolonged by 50%. Systemic clearance is predominantly by hepatic biotransformation to more polar metabolites (quinine 80%, quinidine 65%) and the remaining drug is eliminated unchanged by the kidney. Quinine is well absorbed by mouth or following intramuscular injection even in severe cases of malaria (estimated bioavailability more than 85%). Quinine and chloroquine may cause potentially lethal hypotension if given by intravenous injection.Chloroquine is extensively distributed with an enormous total apparent volume of distribution (Vd) more than 100 L/kg, and a terminal elimination half-life of 1 to 2 months. As a consequence, distribution rather than elimination processes determine the blood concentration profile of chloroquine in patients with acute malaria. Parenteral chloroquine should be given either by continuous intravenous infusion, or by frequent intramuscular or subcutaneous injections of relatively small doses. Oral bioavailability exceeds 75%. Amodiaquine is a pro-drug for the active antimalarial metabolite desethylamodiaquine. Its pharmacokinetic properties are similar to these of chloroquine although the Vd is smaller (17 to 34 L/kg) and the terminal elimination half-life is 1 to 3 weeks.
ISSN:0312-5963
出版商:ADIS
年代:1996
数据来源: ADIS
|
3. |
Warfarin WithdrawalPharmacokinetic-Pharmacodynamic Considerations |
|
Clinical Pharmacokinetics,
Volume 30,
Issue 4,
1996,
Page 300-313
Gualtiero Palareti,
Cristina Legnani,
Preview
|
PDF (6494KB)
|
|
摘要:
Warfarin, like all the 4-hydroxycoumarin compounds, has an asymmetric carbon atom. The clinically available warfarin preparations consist of a racemic mixture of equal amounts of 2 distinctSandRisomers, the former being 4-times more potent as anticoagulant and more susceptible to drug interaction. Warfarin is highly water soluble and rapidly absorbed from the stomach and the upper gastrointestinal tract; its plasma concentrations peak 60 to 90 minutes after oral administration. Warfarin binds to the enzyme vitamin K 2,3-epoxide reductase in liver microsomes, stopping the cycle of vitamin K and reducing &ggr;-carboxylation of the precursors of vitamin D-dependent pro- and anticoagulant factors. A variable fraction of the binding with the target enzyme, albeit small, can be reversed by competitive displacers, such as dithiol-reducing agent activity. Differences in dithiol-reducing activity have been suggested as a contributing factor to the wide interindividual differences in sensitivity to oral anticoagulants. The anticoagulant effect is caused by a small fraction of the drug, since most (97 to 99%) is protein bound (mainly to albumin) and ineffective. Drugs that can displace the albumin binding will increase the action of warfarin, even though this effect is counteracted by a more rapid elimination of the drug. The elimination half-life of warfarin varies greatly among individuals, ranging from 35 to 45 hours; theSisomer has, however, an average half-life shorter than the R isomer.The plasma levels of vitamin K-dependent proteins are determined by a dynamic equilibrium between their synthesis and half-life times. The delay before warfarin takes effect reflects the half-life of the clotting proteins; the levels of factor VII and protein C (with shorter half-lives) are reduced earlier, reaching steady inhibited levels in about 1 day, whereas factor II takes more than 10 days.Oral anticoagulant therapy (OAT) with warfarin or other coumarin derivatives is increasingly administered to patients for primary or secondary prevention of various arterial or venous thromboembolic diseases. If in some clinical conditions OAT is given indefinitely, in others - such as venous thromboembolism or after tissue heart valve replacement - anticoagulants are usually given only for the high risk period of thrombotic complication. A recent large prospective study performed by the Italian Federation of Anticoagulation Clinics showed that about 30% of the patients who began OAT for various clinical indications stopped treatment at different times, confirming that withdrawal from OAT is an occurrence that affects a large number of patients. The expression ‘rebound phenomenon’ was adopted to indicate a hypercoagulant condition occurring after warfarin withdrawal. A possible more frequent recurrence of thromboembolism after cessation of anticoagulation became a matter of controversy and many clinical studies, mostly observational and noncontrolled, reported on the issue with inconsistent results. Most authoritative commentators agreed that rebound phenomenon, though possible, was not clinically relevant and did not differ in frequency and intensity according to mode of withdrawal. Scientific interest in the topic waned until more sensitive methods for investigating blood hypercoagulability became available.In recent years, many studies (reviewed in the text) have investigated the levels of different markers of hypercoagulability [fibrinopeptide A, activated factor VII, prothrombin fragments F1+2, thrombin-antithrombin complexes, D-dimers (DD)], consistently finding an increase in their values after cessation of anticoagulation. Changes in the levels of markers of activated blood coagulation were prospectively investigated by our group in 32 patients with venous thromboembolism who were randomly withdrawn abruptly or gradually from warfarin treatment. Our results indicate that interruption of anticoagulant treatment frequently elicits low grade activation of the haemostatic system, usually not detectable during steady-state anticoagulation. This phenomenon seems to be earlier and more intense after abrupt interruption, but also seems to occur after stepwise withdrawal. Although the activation of coagulation appears to be of limited extent and transient in most cases, it may in a few patients reach higher levels. It seems reasonable to suppose that these patients are at higher risk of thrombotic complications. We and others have suggested that gradual anticoagulant withdrawal would prevent and/or blunt the rebound phenomenon. However, the need to taper the anticoagulant dosage is still uncertain, since no convincing clinical evidence is as yet available. Specifically designed clinical trials are required to solve the issue.
ISSN:0312-5963
出版商:ADIS
年代:1996
数据来源: ADIS
|
4. |
Pharmacokinetic Individualisation of Zidovudine TherapyCurrent State of Pharmacokinetic-Pharmacodynamic Relationships |
|
Clinical Pharmacokinetics,
Volume 30,
Issue 4,
1996,
Page 314-327
Richard M.W. Hoetelmans,
David M. Burger,
Pieter L. Meenhorst,
Jos H. Beijnen,
Preview
|
PDF (5965KB)
|
|
摘要:
Zidovudine is the cornerstone of current antiretroviral treatment of human immunodeficiency virus (HIV) infection. Its use, however, frequently leads to adverse reactions, including myelosuppression. Zidovudine pharmacokinetics show large interindividual variation with indications of pharmacokinetic-pharmacodynamic relationships, but a clear therapeutic window has not yet been defined. Individualisation of zidovudine therapy with monitoring of drug concentrations might be desirable. This review considers (intracellular) monitoring of zidovudine and anabolites for individualisation of zidovudine therapy and the achievements in describing pharmacokinetic-pharmacodynamic relationships so far.
ISSN:0312-5963
出版商:ADIS
年代:1996
数据来源: ADIS
|
|